Avanos Medical (AVNS) Competitors $11.90 -0.21 (-1.74%) Closing price 03:59 PM EasternExtended Trading$11.92 +0.03 (+0.22%) As of 06:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock AVNS vs. EYE, NVCR, LMAT, ENOV, CNMD, CDRE, AORT, ESTA, LQDA, and FNAShould you be buying Avanos Medical stock or one of its competitors? The main competitors of Avanos Medical include National Vision (EYE), NovoCure (NVCR), LeMaitre Vascular (LMAT), Enovis (ENOV), CONMED (CNMD), Cadre (CDRE), Artivion (AORT), Establishment Labs (ESTA), Liquidia Technologies (LQDA), and Paragon 28 (FNA). These companies are all part of the "medical equipment" industry. Avanos Medical vs. Its Competitors National Vision NovoCure LeMaitre Vascular Enovis CONMED Cadre Artivion Establishment Labs Liquidia Technologies Paragon 28 Avanos Medical (NYSE:AVNS) and National Vision (NASDAQ:EYE) are both medical equipment companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, profitability, analyst recommendations, earnings and media sentiment. Do insiders & institutionals have more ownership in AVNS or EYE? 95.2% of Avanos Medical shares are owned by institutional investors. 2.6% of Avanos Medical shares are owned by company insiders. Comparatively, 2.7% of National Vision shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Do analysts rate AVNS or EYE? National Vision has a consensus target price of $23.00, suggesting a potential downside of 9.23%. Given National Vision's stronger consensus rating and higher possible upside, analysts clearly believe National Vision is more favorable than Avanos Medical.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Avanos Medical 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00National Vision 0 Sell rating(s) 4 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.56 Is AVNS or EYE more profitable? National Vision has a net margin of -1.40% compared to Avanos Medical's net margin of -55.80%. Avanos Medical's return on equity of 6.26% beat National Vision's return on equity.Company Net Margins Return on Equity Return on Assets Avanos Medical-55.80% 6.26% 4.63% National Vision -1.40%3.44%1.40% Which has more volatility & risk, AVNS or EYE? Avanos Medical has a beta of 1.12, indicating that its share price is 12% more volatile than the S&P 500. Comparatively, National Vision has a beta of 1.27, indicating that its share price is 27% more volatile than the S&P 500. Does the media prefer AVNS or EYE? In the previous week, National Vision had 5 more articles in the media than Avanos Medical. MarketBeat recorded 10 mentions for National Vision and 5 mentions for Avanos Medical. Avanos Medical's average media sentiment score of 1.30 beat National Vision's score of 1.02 indicating that Avanos Medical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Avanos Medical 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive National Vision 4 Very Positive mention(s) 3 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Which has better earnings and valuation, AVNS or EYE? National Vision has higher revenue and earnings than Avanos Medical. National Vision is trading at a lower price-to-earnings ratio than Avanos Medical, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAvanos Medical$687.80M0.80-$392.10M-$8.37-1.42National Vision$1.82B1.10-$28.50M-$0.33-76.79 SummaryNational Vision beats Avanos Medical on 11 of the 16 factors compared between the two stocks. Get Avanos Medical News Delivered to You Automatically Sign up to receive the latest news and ratings for AVNS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AVNS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AVNS vs. The Competition Export to ExcelMetricAvanos MedicalMED INSTRUMENTS IndustryMedical SectorNYSE ExchangeMarket Cap$550.21M$6.85B$5.67B$21.04BDividend YieldN/A1.30%4.05%3.62%P/E Ratio-1.4225.4427.9427.78Price / Sales0.8060.10396.5871.63Price / Cash1.0020.2736.1922.61Price / Book0.664.738.634.67Net Income-$392.10M$176.14M$3.24B$993.85M7 Day Performance2.11%1.68%3.22%1.16%1 Month Performance-3.85%3.77%10.72%4.99%1 Year Performance-47.35%6.45%34.94%12.53% Avanos Medical Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AVNSAvanos Medical3.3014 of 5 stars$11.90-1.7%N/A-46.6%$550.21M$687.80M-1.422,227News CoverageUpcoming EarningsEYENational Vision2.8027 of 5 stars$25.01+2.2%$22.10-11.6%+91.6%$1.98B$1.82B-75.7913,411Positive NewsAnalyst ForecastNVCRNovoCure3.6974 of 5 stars$17.42-1.0%$32.43+86.2%-12.0%$1.94B$605.22M-11.541,488News CoverageEarnings ReportLMATLeMaitre Vascular2.7001 of 5 stars$84.09+0.5%$97.83+16.3%-8.8%$1.90B$226.26M42.47490Analyst ForecastENOVEnovis2.9296 of 5 stars$31.91-6.2%$55.60+74.3%-39.8%$1.82B$2.15B-2.297,367News CoverageCNMDCONMED4.7324 of 5 stars$50.04-2.4%$62.20+24.3%-31.5%$1.55B$1.31B13.173,900Upcoming EarningsCDRECadre3.3526 of 5 stars$33.47+2.1%$37.50+12.0%-12.3%$1.36B$567.56M35.232,284Dividend AnnouncementAORTArtivion2.9145 of 5 stars$31.68+0.7%$32.40+2.3%+11.8%$1.35B$390.08M-63.361,600News CoverageESTAEstablishment Labs2.0466 of 5 stars$45.53+1.4%$51.80+13.8%-10.1%$1.32B$166.02M-14.691,018LQDALiquidia Technologies3.2872 of 5 stars$14.48+2.8%$26.89+85.7%+53.7%$1.24B$14M-9.1650News CoverageHigh Trading VolumeFNAParagon 28N/A$13.11+0.1%$12.75-2.7%+53.6%$1.10B$256.18M-17.71343,000High Trading Volume Related Companies and Tools Related Companies National Vision Competitors NovoCure Competitors LeMaitre Vascular Competitors Enovis Competitors CONMED Competitors Cadre Competitors Artivion Competitors Establishment Labs Competitors Liquidia Technologies Competitors Paragon 28 Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:AVNS) was last updated on 7/24/2025 by MarketBeat.com Staff From Our PartnersFREE GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...GoldCo Precious Metals | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredStrait of Hormuz = $100 Oil?Dow Drops 540 Points, Oil Soars Middle East conflict sends markets plunging, oil jumping 8.5%. Investors fl...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avanos Medical, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Avanos Medical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.